{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T05:30:34Z","timestamp":1732080634314,"version":"3.28.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,19]]},"DOI":"10.7759\/cureus.73988","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T13:05:34Z","timestamp":1732021534000},"source":"Crossref","is-referenced-by-count":0,"title":["Philadelphia Chromosome as a Clinically Favorable Prognostic Factor of B-cell Acute Lymphoblastic Leukemia\/Lymphoblastic Lymphoma in Transplant-Ineligible Elderly Patients in the Era of Molecular-Targeted Therapy"],"prefix":"10.7759","author":[{"given":"Masuho","family":"Saburi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Uraisami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Takata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Narahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitohiro","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyuki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Ohtsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger T","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017, 7:e577. 10.1038\/bcj.2017.53","journal-title":"Blood Cancer J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber DA","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al.. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016, 127:2391-405. 10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-052746","article-title":"Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol","volume":"109","author":"Vignetti M","year":"2007","unstructured":"Vignetti M, Fazi P, Cimino G, et al.. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007, 109:3676-8. 10.1182\/blood-2006-10-052746","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184093","article-title":"Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation","volume":"113","author":"Bachanova V","year":"2009","unstructured":"Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood. 2009, 113:2902-5. 10.1182\/blood-2008-10-184093","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-14","article-title":"Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)","volume":"6","author":"Nagafuji K","year":"2013","unstructured":"Nagafuji K, Miyamoto T, Eto T, et al.. Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study). J Hematol Oncol. 2013, 6:14. 10.1186\/1756-8722-6-14","journal-title":"J Hematol Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13268","article-title":"Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia","volume":"103","author":"Nagafuji K","year":"2019","unstructured":"Nagafuji K, Miyamoto T, Eto T, et al.. Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia. Eur J Haematol. 2019, 103:164-71. 10.1111\/ejh.13268","journal-title":"Eur J Haematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp MS","year":"2014","unstructured":"Topp MS, G\u00f6kbuget N, Zugmaier G, et al.. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014, 32:4134-40. 10.1200\/JCO.2014.56.3247","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp MS","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, et al.. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015, 16:57-66. 10.1016\/S1470-2045(14)71170-2","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian HM","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, et al.. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016, 375:740-53. 10.1056\/NEJMoa1509277","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes JE","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, et al.. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013, 369:1783-96. 10.1056\/NEJMoa1306494","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes JE","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, et al.. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018, 132:393-404. 10.1182\/blood-2016-09-739086","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"331","author":"Jabbour E","year":"2024","unstructured":"Jabbour E, Kantarjian HM, Aldoss I, et al.. Ponatinib vs imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2024, 331:1814-23. 10.1001\/jama.2024.4783","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda Y","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013, 48:452-8. 10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402526","article-title":"Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study","volume":"16","author":"Takeuchi J","year":"2002","unstructured":"Takeuchi J, Kyo T, Naito K, et al.. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia. 2002, 16:1259-66. 10.1038\/sj.leu.2402526","journal-title":"Leukemia"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe JM","year":"2005","unstructured":"Rowe JM, Buck G, Burnett AK, et al.. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993. Blood. 2005, 106:3760-7. 10.1182\/blood-2005-04-1623","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman AV","year":"2007","unstructured":"Moorman AV, Harrison CJ, Buck GA, et al.. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007, 109:3189-97. 10.1182\/blood-2006-10-051912","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer ML","year":"2009","unstructured":"Den Boer ML, van Slegtenhorst M, De Menezes RX, et al.. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009, 10:125-34. 10.1016\/S1470-2045(08)70339-5","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.4105","article-title":"Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease","volume":"32","author":"Roberts KG","year":"2014","unstructured":"Roberts KG, Pei D, Campana D, et al.. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol. 2014, 32:3012-20. 10.1200\/JCO.2014.55.4105","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros","volume":"453","author":"Mullighan CG","year":"2008","unstructured":"Mullighan CG, Miller CB, Radtke I, et al.. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008, 453:110-4. 10.1038\/nature06866","journal-title":"Nature"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-173963","article-title":"Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP)","volume":"114","author":"Iacobucci I","year":"2009","unstructured":"Iacobucci I, Storlazzi CT, Cilloni D, et al.. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood. 2009, 114:2159-67. 10.1182\/blood-2008-08-173963","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.7836","article-title":"Genetic basis of acute lymphoblastic leukemia","volume":"35","author":"Iacobucci I","year":"2017","unstructured":"Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017, 35:975-83. 10.1200\/JCO.2016.70.7836","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults","volume":"35","author":"Roberts KG","year":"2017","unstructured":"Roberts KG, Gu Z, Payne-Turner D, et al.. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol. 2017, 35:394-401. 10.1200\/JCO.2016.69.0073","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1509318","article-title":"Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients","volume":"60","author":"Miller KC","year":"2019","unstructured":"Miller KC, Al-Kali A, Shah MV, et al.. Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. Leuk Lymphoma. 2019, 60:990-9. 10.1080\/10428194.2018.1509318","journal-title":"Leuk Lymphoma"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Fo\u00e0 R","year":"2011","unstructured":"Fo\u00e0 R, Vitale A, Vignetti M, et al.. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011, 118:6521-8. 10.1182\/blood-2011-05-351403","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0 R","year":"2020","unstructured":"Fo\u00e0 R, Bassan R, Vitale A, et al.. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020, 383:1613-23. 10.1056\/NEJMoa2016272","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Fo\u00e0 R","year":"2024","unstructured":"Fo\u00e0 R, Bassan R, Elia L, et al.. Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL. J Clin Oncol. 2024, 42:881-5. 10.1200\/JCO.23.01075","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour E","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, et al.. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023, 10:e24-34. 10.1016\/S2352-3026(22)00319-2","journal-title":"Lancet Haematol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget N","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, et al.. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018, 131:1522-31. 10.1182\/blood-2017-08-798322","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1780583","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"G\u00f6kbuget N","year":"2020","unstructured":"G\u00f6kbuget N, Zugmaier G, Dombret H, et al.. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2020, 61:2665-73. 10.1080\/10428194.2020.1780583","journal-title":"Leuk Lymphoma"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13375","article-title":"Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia","volume":"104","author":"G\u00f6kbuget N","year":"2020","unstructured":"G\u00f6kbuget N, Dombret H, Giebel S, et al.. Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia. Eur J Haematol. 2020, 104:299-309. 10.1111\/ejh.13375","journal-title":"Eur J Haematol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow MR","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ, et al.. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024, 391:320-33. 10.1056\/NEJMoa2312948","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01766","article-title":"SWOG 1318: A phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"40","author":"Advani AS","year":"2022","unstructured":"Advani AS, Moseley A, O'Dwyer KM, et al.. SWOG 1318: A phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. J Clin Oncol. 2022, 40:1574-82. 10.1200\/JCO.21.01766","journal-title":"J Clin Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32139","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a propensity score analysis","volume":"125","author":"Jabbour EJ","year":"2019","unstructured":"Jabbour EJ, Sasaki K, Ravandi F, et al.. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a propensity score analysis. Cancer. 2019, 125:2579-86. 10.1002\/cncr.32139","journal-title":"Cancer"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2024.100413","article-title":"Successful treatment with blinatumomab for acute lymphoblastic leukemia in an older adult patient complicated with hepatocarcinoma","volume":"21","author":"Saburi M","year":"2024","unstructured":"Saburi M, Sakata M, Maruyama R, et al.. Successful treatment with blinatumomab for acute lymphoblastic leukemia in an older adult patient complicated with hepatocarcinoma. Leuk Res Rep. 2024, 21:100413. 10.1016\/j.lrr.2024.100413","journal-title":"Leuk Res Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/312643-philadelphia-chromosome-as-a-clinically-favorable-prognostic-factor-of-b-cell-acute-lymphoblastic-leukemialymphoblastic-lymphoma-in-transplant-ineligible-elderly-patients-in-the-era-of-molecular-targeted-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T13:05:36Z","timestamp":1732021536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/312643-philadelphia-chromosome-as-a-clinically-favorable-prognostic-factor-of-b-cell-acute-lymphoblastic-leukemialymphoblastic-lymphoma-in-transplant-ineligible-elderly-patients-in-the-era-of-molecular-targeted-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.73988","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,19]]}}}